Lundbeck

Three years strong! We’re proud to share that Lundbeck US has been named a Fortune Best Workplace in BioPharma for the third consecutive year, ranking #10 on the large employers list. This recognition belongs to our people and reflects the culture they create every day — one grounded in purpose, connection, collaboration and a shared commitment to making a difference for patients. Thank you to our colleagues for bringing your passion, perspectives and commitment to work every day. Together, we’re continuing to build a place where people can do meaningful work, grow, belong and make a difference as we advance brain health and transform lives. Interested in joining Lundbeck US? Learn more about our opportunities here:https://bit.ly/4dAQYVR #Fortune #BestWorkplaces

This week, Lundbeck is on the ground in Munich for the 39th European College of Neuropsychopharmacology (ECNP) Congress uniting with global experts across psychiatry, neurology, and psychology, areas of research where Lundbeck has a proud legacy of over 70 years.    At the congress, which began on World Mental Health Day, we are convening discussions on AI in clinical practice, the importance of patient preferences in treatment plans, and patient-centric care, as we work together to shape the future of brain health . If you are attending #ECNP, stop by the Lundbeck booth to connect with our team.     #Neuroscience #BrainHealth  #WorldMentalHealthDay

For over 70 years, Lundbeck has been dedicated to advancing brain health through science, advocacy, and partnership.   Our legacy is rooted in a fundamental belief: when people’s minds are healthy, they can flourish in all aspects of life.     On #WorldMentalHealthDay, as we collectively raise awareness about the importance of prioritizing mental health, we remain committed to challenging the stigma associated with brain health & mental wellbeing and addressing the obstacles that prevent people from thriving.     This video truly captures this legacy.     We are proud of our incredible journey and look forward to advancing brain health through scientific innovation and greater awareness.      #WorldMentalHealthDay #BrainHealth #Neuroscience  

As #MDSCongress comes to a close, we are leaving Seoul energized by five days of incredible scientific exchange. Hats off to the International Parkinson and Movement Disorder Society for bringing together the global movement disorders community at this pivotal event.      Throughout the week, Lundbeck was proud to present new research across multiple system atrophy (MSA) and Parkinson's disease.     A sincere thank you to all the presenters and attendees whose dedication continues to drive progress for patients and families living with neurological diseases. And now, our work continues...

Lundbeck is joining the Antibody Developability Consortium, alongside AbbVie, argenx, and Takeda. Together with Ginkgo Datapoints and Apheris, we're building predictive AI models for antibody developability, trained on a shared, standardized dataset. In complex therapeutic areas such as CNS, the ability to select well-behaved candidates with strong developability properties is essential. By bringing together a diverse antibody dataset under a common characterization standard, and keeping proprietary sequences private through federated infrastructure, this collaboration strengthens predictive approaches and supports better-informed decisions earlier in drug discovery. Read more in this press release: https://lnkd.in/gaanpa_2 #AntibodyDevelopment #FederatedLearning #DrugDiscovery #DataPrivacy

Yesterday at #MDS2026, Lundbeck brought together international experts for a scientific symposium exploring some of the key challenges in multiple system atrophy (MSA) -  from earlier recognition to understanding disease progression.    Discussions explored approaches to identifying possible prodromal MSA, the considerable variability in disease progression, and the evolving role of biomarkers in diagnosis, prognosis and monitoring progression.    Advancing our understanding of these areas is important as the scientific community works towards better ways to identify, measure and ultimately address this rare and rapidly progressing neurological disease.    A big thank you to Dr. Wassilios Meissner, Dr. Horacio Kaufmann and Dr. Hirohisa Watanabe    #MSA #MovementDisorders #Neuroscience #MDS2026 #PRESS Read more: https://lnkd.in/eKTADGxN

Recently, we welcomed a delegation of doctors and healthcare professionals from AMA Queensland to Lundbeck’s headquarters in Valby, Copenhagen. The visit offered an opportunity to share Lundbeck’s focused commitment to brain health, from the complexity of neuroscience research to the work required to translate scientific insight into potential new treatments. Together, we discussed the importance of long-term investment in research, collaboration across the life science ecosystem, and the conditions that help innovation create meaningful patient impact. We were pleased to share perspectives from our R&D and Public Affairs colleagues, as well as the distinctive Danish context in which Lundbeck operates, including our foundation ownership model and close collaboration across research, healthcare, industry and public authorities. Thank you to AMA Queensland for the thoughtful dialogue and for visiting us. International exchange is an important part of advancing brain health and improving the lives of people living with brain diseases. #BrainHealth #Neuroscience #LifeScience #Innovation #Collaboration

On World MSA Day, we stand alongside individuals and their families navigating Multiple System Atrophy (MSA) to raise awareness of this rare, rapidly progressing neurodegenerative disease that remains widely underrecognized.    MSA is a complex neurological disease involving progressive damage to nerve cells in areas of the brain involved in balance, movement and essential bodily functions. Over time, MSA robs people of their independence, ability to perform simple daily activities and time with loved ones.  For patients and families, navigating the disease often involves a long road to diagnosis and a search for clarity in a landscape where so much remains unknown.    🧠🔬 This reality drives our purpose at Lundbeck and it is precisely why research and innovation matter so deeply to us. We are committed to pushing the boundaries of neuroscience to better understand rare brain disorders, champion early diagnosis, and bring hope to families affected by MSA.    Ann’s courage reinforces our dedication to brain health and patient advocacy. We invite you to read her full story at the link below.    #WorldMSADay #MultipleSystemAtrophy #RareDisease #NeuroNarratives

We’re heading to Seoul for #MDSCongress!    Lundbeck will present new research across neurological movement disorders at the International Parkinson and Movement Disorder Society Congress, taking place 4–8 October.    Our presentations will share new insights into multiple system atrophy (MSA), a rare and rapidly progressive neurodegenerative disease, and advanced Parkinson’s disease (PD) where high-unmet need remains.    #PRESS Read more in the Lundbeck Newsroom: https://lnkd.in/eKTADGxN

For many people living with migraine, finding effective ways to manage the disease can be a long and complex journey.    Despite advances in migraine prevention, some people continue to experience a substantial burden from the disease, highlighting the need for continued research and a better understanding of how migraine can be managed optimally.    Today, we announced new clinical research that contributes to the growing scientific understanding of migraine prevention, including what may come next when a previous preventive approach has not achieved adequate response.    At Lundbeck, we remain committed to advancing migraine research and generating evidence that can help address important questions for healthcare physicians and people living with this disabling neurological disease.    Read more about it in our recent press release: https://lnkd.in/eKTADGxN